Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?
Akebia Therapeutics Ownership Summary
Akebia Therapeutics is owned by 45.98% institutional investors, 3.56% insiders, and 50.46% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.80% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in Akebia Therapeutics shares.
AKBA Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Akebia Therapeutics | 45.98% | 3.56% | 50.46% |
Sector | Healthcare Stocks | 486.50% | 11.08% | -397.59% |
Industry | Biotech Stocks | 304.14% | 11.08% | -215.23% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock funding, inc. /de | 18.37M | 7.80% | $66.88M |
Blackrock | 11.64M | 5.68% | $11.87M |
Vanguard group | 10.88M | 5.17% | $20.68M |
State street | 6.30M | 3.00% | $11.98M |
Alerce investment management | 5.75M | 2.73% | $10.92M |
Geode capital management | 4.80M | 2.28% | $9.11M |
Renaissance | 3.82M | 1.82% | $7.26M |
Bioimpact capital | 2.89M | 1.23% | $10.52M |
Jacobs levy equity management | 2.09M | 1.02% | $2.14M |
Nantahala capital management | 2.00M | 0.85% | $7.28M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Alerce investment management | 5.75M | 19.23% | $10.92M |
Great point partners | 1.99M | 4.70% | $7.23M |
Bioimpact capital | 2.89M | 1.82% | $10.52M |
Affinity asset advisors | 1.95M | 0.97% | $7.10M |
Nantahala capital management | 2.00M | 0.29% | $7.28M |
Orchard capital management | 53.51K | 0.22% | $194.78K |
Diametric capital, lp | 57.53K | 0.11% | $209.42K |
Entrypoint capital | 41.00K | 0.07% | $149.22K |
Wealth effects | 34.50K | 0.05% | $125.58K |
Alphamark advisors | 38.46K | 0.03% | $73.00K |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Blackrock | 11.64M | 0.00% | 9.10M |
Blackrock funding, inc. /de | 18.37M | 0.00% | 3.04M |
Bioimpact capital | 2.89M | 1.82% | 2.89M |
State street | 6.30M | 0.00% | 2.87M |
Acadian asset management | 1.35M | 0.01% | 1.35M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Great point partners | 1.99M | 4.70% | -2.99M |
Aigh capital management | - | - | -2.92M |
Monashee investment management | - | - | -1.50M |
Balyasny asset management | 9.15K | 0.00% | -1.24M |
Axa | - | - | -627.89K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Bioimpact capital | 2.89M | 1.82% | 2.89M | $10.52M |
Acadian asset management | 1.35M | 0.01% | 1.35M | $4.91M |
Exoduspoint capital management, lp | 289.53K | 0.01% | 289.53K | $1.05M |
Walleye capital | 214.82K | 0.00% | 214.82K | $781.93K |
Alps advisors | 141.66K | 0.00% | 141.66K | $515.66K |
Sold Out
Holder | Change |
---|---|
Northwestern mutual wealth management | -5.00 |
Capital performance advisors llp | -68.00 |
Hexagon capital partners | -186.00 |
Laurel wealth advisors | -229.00 |
Redwood wealth management group | -300.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2025 | 162 | 8.72% | 108,281,334 | 13.45% | 45 | 2.80% | 111 | 19.35% | 23 | -11.54% |
Mar 31, 2025 | 150 | 19.05% | 95,500,610 | 40.77% | 40 | 3.90% | 94 | 34.29% | 27 | 22.73% |
Dec 31, 2024 | 124 | 4.20% | 67,787,367 | 14.05% | 32 | 4.04% | 70 | 18.64% | 22 | -15.38% |
Sep 30, 2024 | 118 | 9.26% | 59,390,703 | 5.52% | 28 | 3.74% | 59 | 9.26% | 26 | 8.33% |
Jun 30, 2024 | 108 | -14.29% | 56,234,084 | -1.41% | 27 | 3.04% | 53 | -27.40% | 24 | - |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Total Stock Mkt Idx Inv | 7.79M | 2.96% | -172.84K |
Vanguard US Total Market Shares ETF | 5.95M | 2.52% | - |
iShares Russell 2000 ETF | 5.93M | 2.26% | -112.77K |
SPDR® S&P Biotech ETF | 3.08M | 1.17% | 76.01K |
Vanguard Institutional Extnd Mkt Idx Tr | 2.59M | 0.99% | -1.16M |
Fidelity Small Cap Index | 2.19M | 0.83% | 3.43K |
Nuveen Quant Small Cap Equity R6 | 2.07M | 0.79% | -41.26K |
Foord Global Equity (Lux) A | 1.99M | 0.76% | 1.99M |
iShares Russell 2000 Value ETF | 1.95M | 0.74% | 1.45K |
Foord Global Equity Class B | 1.83M | 0.70% | 1.83M |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jun 30, 2025 | Ostrowski Erik | SVP, CFO, CBO & Treasurer | Sell | $151.62K |
Jun 09, 2025 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $60.15K |
Jun 04, 2025 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $47.07K |
Mar 03, 2025 | Butler John P. | CEO and President | Sell | $84.93K |
Mar 03, 2025 | Burke Steven Keith | SVP, Chief Medical Officer | Sell | $13.07K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | 3 |
2025 Q1 | - | 8 |
2024 Q2 | - | 2 |
2024 Q1 | - | 10 |
2023 Q3 | - | 1 |
AKBA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools